Ocular Therapeutix reported a net loss of $15 million, or $0.38 per share, in the third quarter of 2018 compared with a net loss of $15.6 million, or $0.54 per share, in 2017’s third quarter.
Revenues for the quarter totaled $0.5 million, driven exclusively by ReSure Sealant, according to a press release.
Selling and marketing expenses decreased from $3.2 million in 2017’s third quarter to $1.1 million this year, which was attributed to a reduction in pre-commercial activities due to a delay in the planned release of Dextenza (dexamethasone insert (Read more...)
Uncategorized